文献速递妇科肿瘤

肿瘤科医生主导的卵巢癌BRCA突变检测与咨询简化模型评估

Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
PubMed 文献 · J Clin Oncol · 2018-03-20

ENGAGE前瞻性观察研究在美、意、西26个中心纳入700例卵巢癌患者,评估肿瘤科医生主导的BRCA突变检测路径。中位总周转时间9.1周,患者满意度超99%,肿瘤科医生满意度超80%,表明该路径可行。

要点

  • 肿瘤科医生主导BRCA检测路径在卵巢癌中可行
  • 中位总周转时间9.1周,各国差异明显
  • 患者和肿瘤科医生满意度高,可减轻遗传咨询师压力

核心结论

  • ENGAGE研究证明肿瘤科医生主导的BRCA突变检测流程在卵巢癌中可行。
  • 制定类似本研究的本地BRCA检测指南可加快治疗决策并更好利用资源。

研究设计与样本

  • 前瞻性观察性ENGAGE研究,评估肿瘤科医生主导的简化BRCA突变检测路径。
  • 分析人群为美国、意大利和西班牙26个中心的700例卵巢癌患者。
  • 主要目标为评估周转时间,并通过问卷评估患者、肿瘤科医生和遗传学家或遗传咨询师的满意度。

主要发现

  • 中位总周转时间为9.1周(范围0.9至37.1周)。
  • 美国中位周转时间4.1周(范围0.9至37.1周),意大利20.4周(范围2.9至35.4周),西班牙12.0周(范围2.0至36.7周)。
  • 超过99%的患者对BRCA突变检测前后咨询表示满意。
  • 超过80%的肿瘤科医生同意检测流程运行良好且咨询是高效利用时间。
  • 肿瘤科医生对检测路径的满意度高于遗传学家或遗传咨询师。

临床怎么用

  • 卵巢癌患者BRCA突变检测可由肿瘤科医生主导实施,以缩短检测周转时间并缓解遗传咨询师不足的压力。
  • 可参考本研究路径制定本地BRCA检测指南,以加快治疗决策和优化资源利用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose There is a growing demand for BRCA1/ 2 mutation ( BRCAm) testing in patients with ovarian cancer; however, the limited number of genetic counselors presents a potential barrier. To facilitate more widespread BRCAm testing in ovarian cancer, pretest counseling by the oncology team could shorten testing turnaround times and ease the pressure on genetic counselors. Patients and Methods The prospective, observational Evaluating a Streamlined Onco-genetic BRCA Testing and Counseling Model Among Patients With Ovarian Cancer (ENGAGE) study evaluated a streamlined, oncologist-led BRCAm testing pathway. The analysis population comprised 700 patients with ovarian cancer at 26 sites in the United States, Italy, and Spain. The primary objectives were to assess turnaround time and, using questionnaires, to evaluate stakeholder satisfaction (patients, oncologists, and geneticists or genetic counselors) with the oncologist-led BRCAm testing pathway. Results The median overall turnaround time was 9.1 weeks (range, 0.9 to 37.1 weeks), with median turnaround times in the United States, Italy, and Spain of 4.1 weeks (range, 0.9 to 37.1 weeks), 20.4 weeks (range, 2.9 to 35.4 weeks), and 12.0 weeks (range, 2.0 to 36.7 weeks), respectively. Patient satisfaction with the oncologist-led BRCAm testing pathway was high, with > 99% of patients expressing satisfaction with pre- and post- BRCAm test counseling. Oncologist satisfaction with the BRCAm testing pathway was also high, with > 80% agreeing that the process for performing BRCAm testing worked well and that counseling patients on BRCAm testing was an efficient use of their time. Oncologists expressed higher levels of satisfaction with the BRCAm testing pathway than did geneticists or genetic counselors. Conclusion The results of the ENGAGE study demonstrate that an oncologist-led BRCAm testing process is feasible in ovarian cancer. Development of local BRCAm testing guidelines similar to the one used in this study could allow faster treatment decisions and better use of resources in the management of patients with ovarian cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Colombo N, Huang G, Scambia G, et al. Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer. J Clin Oncol. 2018. PMID: 29558274. doi:10.1200/JCO.2017.76.2781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。